Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 2/2019

02.01.2019 | Clinical Investigation

Night-vision aid using see-through display for patients with retinitis pigmentosa

verfasst von: Yasuhiro Ikeda, Shunji Nakatake, Jun Funatsu, Kohta Fujiwara, Takashi Tachibana, Yusuke Murakami, Toshio Hisatomi, Shigeo Yoshida, Hiroshi Enaida, Tatsuro Ishibashi, Koh-Hei Sonoda

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

From an early stage, retinitis pigmentosa (RP) patients suffer from night blindness which causes nocturnal mobility difficulties. We created a wearable visual aid that uses a high-performance see-through display, and added a high-sensitivity camera with a complementary metal-oxide-semiconductor sensor. Here, we evaluate the device’s efficacy for helping night-blindness sufferers walk in the dark.

Study design

Prospective clinical study.

Methods

Twenty-eight subjects underwent binocular visual acuity testing in the dark without (power off) and with (power on) the device. The test was carried out in a darkened room. We recorded the number of trial errors and the time it took each subject to arrive at the goal both with and without the aid of our device.

Results

Our device effectively assists walking in RP patients with mobility problems in the dark.

Conclusion

Binocular visual acuity in the dark was significantly improved with the aid of our device. In the walking test, the number of errors decreased greatly with the device, and the travel time was significantly shortened.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–60.CrossRefPubMedPubMedCentral Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–60.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med. 2015;372:1887–97.CrossRefPubMedPubMedCentral Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med. 2015;372:1887–97.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Jacobson SG, Cideciyan AV, Aguirre GD, Sumaroka A, Schwartz SB, Heon E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372:1920–6.CrossRefPubMedPubMedCentral Jacobson SG, Cideciyan AV, Aguirre GD, Sumaroka A, Schwartz SB, Heon E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372:1920–6.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Edwards TL, Jolly JK, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, et al. Visual Acuity after Retinal Gene Therapy for Choroideremia. N Engl J Med. 2016;374:1996–8.CrossRefPubMedPubMedCentral Edwards TL, Jolly JK, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, et al. Visual Acuity after Retinal Gene Therapy for Choroideremia. N Engl J Med. 2016;374:1996–8.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509–16.CrossRefPubMed Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509–16.CrossRefPubMed
6.
Zurück zum Zitat Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376:1038–46.CrossRefPubMed Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376:1038–46.CrossRefPubMed
7.
Zurück zum Zitat Berson EL, Mehaffey L 3rd, Rabin AR. A night vision device as an aid for patients with retinitis pigmentosa. Arch Ophthalmol. 1973;90:112–6.CrossRefPubMed Berson EL, Mehaffey L 3rd, Rabin AR. A night vision device as an aid for patients with retinitis pigmentosa. Arch Ophthalmol. 1973;90:112–6.CrossRefPubMed
8.
Zurück zum Zitat Berson EL, Mehaffey L 3rd, Rabin AR. A night vision pocketscope for patients with retinitis pigmentosa: design considerations. Arch Ophthalmol. 1974;91:495–500.CrossRefPubMed Berson EL, Mehaffey L 3rd, Rabin AR. A night vision pocketscope for patients with retinitis pigmentosa: design considerations. Arch Ophthalmol. 1974;91:495–500.CrossRefPubMed
9.
Zurück zum Zitat Morrissette DL, Marmor MF, Goodrich GL. An evaluation of night vision mobility aids. Ophthalmology. 1983;90:1226–30.CrossRefPubMed Morrissette DL, Marmor MF, Goodrich GL. An evaluation of night vision mobility aids. Ophthalmology. 1983;90:1226–30.CrossRefPubMed
10.
Zurück zum Zitat Friedburg C, Serey L, Sharpe LT, Trauzettel-Klosinski S, Zrenner E. Evaluation of the night vision spectacles on patients with impaired night vision. Graefes Arch Clin Exp Ophthalmol. 1999;237:125–36.CrossRefPubMed Friedburg C, Serey L, Sharpe LT, Trauzettel-Klosinski S, Zrenner E. Evaluation of the night vision spectacles on patients with impaired night vision. Graefes Arch Clin Exp Ophthalmol. 1999;237:125–36.CrossRefPubMed
11.
Zurück zum Zitat Spandau UH, Wechsler S, Blankenagel A. Testing night vision goggles in a dark outside environment. Optom Vis Sci. 2002;79:39–45.CrossRefPubMed Spandau UH, Wechsler S, Blankenagel A. Testing night vision goggles in a dark outside environment. Optom Vis Sci. 2002;79:39–45.CrossRefPubMed
12.
Zurück zum Zitat Bowers AR, Luo G, Rensing NM, Peli E. Evaluation of a prototype minified augmented-view device for patients with impaired night vision. Ophthalmic Physiol Opt. 2004;24:296–312.CrossRefPubMed Bowers AR, Luo G, Rensing NM, Peli E. Evaluation of a prototype minified augmented-view device for patients with impaired night vision. Ophthalmic Physiol Opt. 2004;24:296–312.CrossRefPubMed
13.
Zurück zum Zitat Hartong DT, Jorritsma FF, Neve JJ, Melis-Dankers BJ, Kooijman AC. Improved mobility and independence of night-blind people using night-vision goggles. Invest Ophthalmol Vis Sci. 2004;45:1725–31.CrossRefPubMed Hartong DT, Jorritsma FF, Neve JJ, Melis-Dankers BJ, Kooijman AC. Improved mobility and independence of night-blind people using night-vision goggles. Invest Ophthalmol Vis Sci. 2004;45:1725–31.CrossRefPubMed
14.
Zurück zum Zitat Hartong DT, Kooijman AC. Night-vision goggles for night-blind subjects: subjective evaluation after 2 years of use. Ophthalmic Physiol Opt. 2006;26:490–6.CrossRefPubMed Hartong DT, Kooijman AC. Night-vision goggles for night-blind subjects: subjective evaluation after 2 years of use. Ophthalmic Physiol Opt. 2006;26:490–6.CrossRefPubMed
15.
Zurück zum Zitat Ikeda Y, Suzuki E, Kuramata T, Kozaki T, Koyama T, Kato Y, et al. Development and evaluation of a visual aid using see-through display for patients with retinitis pigmentosa. Jpn J Ophthalmol. 2015;59:43–7.CrossRefPubMed Ikeda Y, Suzuki E, Kuramata T, Kozaki T, Koyama T, Kato Y, et al. Development and evaluation of a visual aid using see-through display for patients with retinitis pigmentosa. Jpn J Ophthalmol. 2015;59:43–7.CrossRefPubMed
16.
Zurück zum Zitat Sugawara T, Hagiwara A, Hiramatsu A, Ogata K, Mitamura Y, Yamamoto S. Relationship between peripheral visual field loss and vision-related quality of life in patients with retinitis pigmentosa. Eye (Lond). 2010;24:535–9.CrossRefPubMed Sugawara T, Hagiwara A, Hiramatsu A, Ogata K, Mitamura Y, Yamamoto S. Relationship between peripheral visual field loss and vision-related quality of life in patients with retinitis pigmentosa. Eye (Lond). 2010;24:535–9.CrossRefPubMed
Metadaten
Titel
Night-vision aid using see-through display for patients with retinitis pigmentosa
verfasst von
Yasuhiro Ikeda
Shunji Nakatake
Jun Funatsu
Kohta Fujiwara
Takashi Tachibana
Yusuke Murakami
Toshio Hisatomi
Shigeo Yoshida
Hiroshi Enaida
Tatsuro Ishibashi
Koh-Hei Sonoda
Publikationsdatum
02.01.2019
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 2/2019
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-018-00644-5

Weitere Artikel der Ausgabe 2/2019

Japanese Journal of Ophthalmology 2/2019 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.